Practices

Mergers and Acquisitions

1,600+ M&A transactions for an aggregate value of $735 billion+ since 2020

Why Cooley

  • 180+ member team in 19 major business and technology centers in the US, Europe and Asia

  • Broad industry platform with clients across many industries and sophisticated capabilities in all practice areas

  • Excel in deals in the tech, life sciences, artificial intelligence, medical device and healthcare, consumer, education, defense and media industries

  • Given our market position in the medtech and life sciences sectors, we have handled a large number of life sciences M&A transactions, both public and private, and understand unique structuring issues for life sciences companies, including milestone structures, contingent value rights and option structures

  • Primary corporate counsel to 250+ public companies, giving us an unmatched perspective on market deal points and ability to facilitate introductions between buyers and sellers

  • Represent all categories of participants in transactions, including buyers, sellers, major stockholders, venture capitalists, lenders, financial advisors, management/founders, special board committees, individual investors, private equity funds, hedge funds and others

  • Adept at handling all manner of transactions, including domestic and cross-border mergers and acquisitions; strategic deals, including joint ventures, acquisitions of IP assets, patent cross-licenses, complex divestitures and spinoffs; takeover defense and shareholder activism counseling; and multibillion-dollar public company mergers

  • Robust SPAC (special purpose acquisition company) experience and thought leaders in the area, with a repository of market insight and guidance for businesses interested in the IPO alternative

  • Market-leading IP, privacy, technology licensing, life sciences collaborations and licensing, regulatory, government contracts, credit finance, private equity, antitrust, employment, compensation and tax practices to support transactions

Read more

Recognition

  • Chambers: USA – Nationwide Corporate/M&A: The Elite
  • Bloomberg: #2 for US M&A by Deal Count (2024)
  • Bloomberg: #4 for Global M&A by Deal Count (2024)
  • Bloomberg: #2 for US Mid-Market M&A by Deal Count (2024)
  • Bloomberg: #3 for Global Mid-Market M&A by Deal Count (2024)
  • Mergermarket: #5 for US M&A by Deal Count (2024)
  • Mergermarket: #6 for Global M&A by Deal Count (2024)
  • LMG Life Sciences: M&A Firm of the Year (2023)